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Summary. Background: In order to stratify patients with
a first unprovoked venous thromboembolism (VTE)
according to their recurrence risk and to identify those
who would actually benefit from indefinite anticoagula-
tion, three prediction models have been developed so
far; none of them has been yet externally validated.
Objective: To externally validate the Vienna Prediction
Model (VPM), a prediction guide for estimating the
recurrence risk after a first unprovoked VTE developed
through Cox modeling and including sex, D-dimer and
index VTE site as predictors. Patients/Methods: Nine
hundred and four patients pooled from five prospective
studies evaluating the prognostic value of D-dimer for
VTE recurrence served as the validation cohort. The
validity of the VPM in stratifying patients according to
their relative recurrence risk (discrimination) and in pre-
dicting the absolute recurrence risk (calibration) was
tested with survival analysis methods. Results: The abil-
ity of the VPM to distinguish patients’ risk for recurrent
VTE in the validation cohort was at least as good as in
the original cohort, with a calibration slope of 1.17
(95% confidence interval 0.71–1.64; P = 0.456 for the
hypothesis of a significant difference from 1), and a c-
statistic of 0.626 (vs. 0.651 in the original derivation
cohort). The VPM absolute predictions in terms of
cumulative rates tended to underestimate the observed
recurrence rates at 12 months. Conclusions: By using a
pooled individual patient database as a validation
cohort, we confirmed the ability of the VPM to stratify
patients with a first unprovoked VTE according to their
risk of recurrence.
Keywords: decision support technique; pulmonary embolism;
recurrence; venous thromboembolism; venous thrombosis.
Introduction
Patients with unprovoked venous thromboembolism
(VTE) who have received 3–6 months of anticoagulant
therapy have a recurrence risk of 5–10% per year after
anticoagulation is stopped [1–3]. The challenge for the
clinician is to stratify such patients according to their
risk of recurrent VTE, so as to distinguish patients
who would derive a net clinical benefit from indefinite
anticoagulant therapy from those in whom long-term
anticoagulation would not be justified. Several clinical
and laboratory risk factors have been identified as
determinants of recurrence risk in patients with unpro-
voked VTE [4,5]. Three clinical prediction models,
which have embedded some of these risk factors, have
been developed but are not yet validated [6–8]. Among
these prediction models, the Vienna Prediction Model
(VPM) [7] provides an easy-to-use web-based risk
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calculator (http://cemsiis.meduniwien.ac.at/en/kb/science-
research/software/clinical-software/recurrent-vte/) that
incorporates patient sex, VTE site and D-dimer to esti-
mate VTE recurrence risk in individual patients after
anticoagulation is stopped. Validating a clinical predic-
tion model such as the VPM in an independent popula-
tion is a pivotal step towards confirming its validity
and generalizability [9,10]. This step should comprise
both the quantification of the model’s ability to distin-
guish between patients with and those without the event
of interest (discrimination), and a comparison between
observed and predicted event rates for groups of
patients (calibration) [9,10].
We aimed to externally validate the VPM by using an
independent individual patient dataset that was pooled
from prospective cohort studies that assessed, in part, the
clinical utility of D-dimer in predicting recurrent VTE.
We used methods proposed in the literature to validate
predictive models that were developed, as with the VPM,
by the use of Cox (time-to-event) analyses [9,11,12].
Methods
VPM
The VPM was derived from 929 patients with unpro-
voked VTE (derivation cohort) recruited from four
thrombosis centers in Vienna, Austria, between 1992 and
2008 [7]. In this cohort, the following patients were
excluded: women with estrogen-associated VTE; patients
with a deficiency of antithrombin, protein C, or pro-
tein S, or with a lupus anticoagulant; double heterozy-
gous or homozygous carriers of the factor V Leiden and
prothrombin mutations; and patients with cancer-associ-
ated VTE. The VPM was based on a multivariable Cox
regression of seven candidate risk factors, comprising age,
sex, VTE site (pulmonary embolism, proximal deep vein
thrombosis, or distal deep vein thrombosis), body mass
index, factor V Leiden, prothrombin mutation, and D-
dimer measured after anticoagulant therapy had been
stopped. Only sex, VTE site and D-dimer were significant
predictors of the recurrence risk and were included in the
final model [7].
Validation cohort
We validated the VPM in a multicohort dataset compris-
ing individual patient data originally obtained from seven
prospective studies that included the Vienna study [13–
19]. We found no significant heterogeneity between the
seven studies in a previous meta-analysis evaluating the
predictive value of D-dimer for recurrent VTE [1,20]. To
obtain an independent validation cohort for this analysis,
we excluded the Vienna study from this multicohort data-
base. To ensure consistency of patient characteristics in
the derivation and validation cohorts, we excluded
women with estrogen-associated VTE (not included in the
Vienna study), patients with missing D-dimer data, and
patients with incomplete data for classification of the
index VTE site. Patients excluded because of missing or
incomplete data (n = 266) differed slightly from those
included in the validation cohort (n = 904), as the propor-
tion of males (51.5% vs. 60.5%) and median age (median
64 years vs. 68 years) were lower. No differences were
found regarding the frequency of and time to VTE recur-
rence (P = 0.59 for by-study stratified analysis). Figure 1
summarizes the generation of the validation cohort from
the original multistudy database. To meet the above-men-
tioned criteria, the final validation cohort was composed
of patients derived from five of the seven original studies.
All patients in the derivation and validation cohorts
received at least 3 months of anticoagulant therapy and
had follow-up for symptomatic recurrent VTE, which
comprised deep vein thrombosis and/or pulmonary embo-
lism. All outcome events were objectively confirmed by
compression ultrasound, lung scanning, or computed
tomography.
Statistical analysis
For the VPM, not only the relative risk (in terms of haz-
ard ratios [HRs]) associated with each risk factor (sex,
index VTE site, and D-dimer) [7] but also the Cox-
derived cumulative hazards (or cumulative rates) of recur-
rent VTE at 12 months were provided in the form of a
risk calculator. From the latter, we could approximate
the predicted baseline risks and calculate the cumulative
rates of recurrence at that time point for each patient of
the validation cohort. In this way, we could test both the
discrimination and calibration of the VPM in the valida-
tion cohort.
Validation of the predicted relative risk of recurrence
(discrimination)
First, we assessed the validity of the predicted relative
risk of recurrence associated with the predictors in the
VPM (sex, index VTE site, and D-dimer), also called the
prognostic index [12]. The Vienna prognostic index
(XbVienna) corresponded to the linear predictor from the
Vienna Cox model, which was calculated for each patient
as the sum of the predictors weighted for the correspond-
ing Cox regression coefficients (back-calculated from the
published HR). XbVienna expresses the risk of an individ-
ual as compared with an individual with a prognostic
index of 0, so that patients or groups with higher values
for XbVienna have a worse prognosis [12]. Thus, we calcu-
lated XbVienna for each patient of the validation set, and
then we performed a Cox regression in the validation
cohort with time-to-recurrence as outcome and XbVienna
as predictor. The regression coefficient (a) thus obtained
for XbVienna, also called the calibration slope, provided
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information for both the discrimination and the calibra-
tion/accuracy of the VPM in the validation cohort (taking
into account that the same coefficient would be, by defini-
tion, equal to 1 in the derivation cohort) [11,12]. Discrim-
ination of the VPM in the validation cohort was also
measured by the use of Harrell’s c-statistic. Further
details of these statistical methods are provided in
Data S1.
Validation of the predicted absolute risk of recurrence
(calibration)
We next evaluated the performance of the VPM by test-
ing the accuracy of the predictions of the absolute risk
(cumulative rates) made by the VPM in the validation
cohort at 12 months. We first used the common graphical
calibration approach (calibration plot), in which absolute
predicted and observed risks (taking into account the
time-to-event) were plotted. In particular, we plotted
the VPM-predicted and the observed cumulative rates in
the validation cohort for five groups (quintiles) at increas-
ing predicted risk [9,12]. We repeated the analysis with a
higher number of groups (20). The observed cumulative
rates for each group were calculated with the Nelson–
Aalen estimator at 12 months. A random effect model
was used to test the statistical significance of the differ-
ence between observed and predicted cumulative rates.
We adopted an additional approach to further test cali-
bration, i.e. the use of a parametric survival model,
which, unlike a Cox model, allows the function for the
baseline risk of recurrence to be parameterized. Detains
of the method are shown in Data S2.
Sensitivity analyses
As the Vienna derivation cohort was, on average, younger
than the validation cohort (Table 1), the validation pro-
cesses were repeated with a subset of the validation cohort
comprising only patients aged ≤ 65 years (Data S3).
To account for the multistudy nature of the individual
patient database, all survival semiparametric and para-
metric models were performed with and without stratifica-
tion by study. The proportional hazard assumption of the
Cox calibrating models was checked by the use of
Schoenfeld’s residuals. All analyses were performed with
STATA statistical software , version 12.0 (StataCorp 800-
STATAPC, College Station, TX, USA).
Results
Patient characteristics
Table 1 compares the patient characteristics of the deriva-
tion and validation cohorts. Patients included in the vali-
dation cohort tended to be older with less frequent
presentation of the index event as distal vein thrombosis,
and with higher postanticoagulation D-dimer levels, than
those included in the derivation cohort. The overall med-
ian postanticoagulation follow-up was 22 months (25th,
75th percentiles: 14 months, 29 months) in the validation
IPD D-dimer database
Hormone-related VTE excluded
Patients excluded because of
missing quantitative D-dimer data
Eichinger et al. study [16] 
excluded in order to have a
excluded because of unavailable
data to classify the first VTE site
according to the definition used
in the derivation cohort
 VALIDATION COHORT
validation cohort independent 
of the derivation cohort as they were in the derivation
cohort
No. of patients with a first unprovoked VTE 1818
No. of patients 226
No. of patients 243
No. of patients 1170
No. of patients 904
No. of studies 7 [13–19]
No. of studies 1
No. of studies 1
No. of studies 5 [15,16,19–21]
No. of patients 422
No. of patients 23
No. of studies 6 [13–15, 17–19]
Shrivastava et al. study [17] 
Fig. 1. Flow chart: generation of the validation cohort from the multistudy D-dimer database. IPD, individual patient data; VTE, venous
thromboembolism.
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cohort, and 43 months (25th, 75th percentiles: 15 months,
78 months) in the derivation cohort [7].
There were 123 (13.6%) recurrent VTEs in the valida-
tion cohort, of which 84 (68.3%) occurred during the first
year after anticoagulation had been stopped. The cumula-
tive rates of recurrent VTE after 1 year and 5 years were
10.0% (95% confidence interval [CI] 8.1–12.4%) and
30.7% (95% CI 21.3–44.2%), respectively (Fig. 2). As
few studies in the validation cohort had data after 2 years
of patient follow-up (Fig. 2), we restricted our analysis to
12 months. Table 2 compares the observed frequency of
recurrence (as raw frequencies and cumulative rates) with
the cumulative rates at 12 months predicted by the VPM
for five risk groups in the validation cohort.
VPM validation
The Cox calibration slope a had a point estimate of 1.2,
which was not statistically significantly different from 1,
indicating that XbVienna had equal-to-better discrimina-
tion in the validation cohort than in the derivation
cohort, as confirmed by the c-statistic being slightly lower
than in the derivation cohort (0.626 vs. 0.651; Data S1).
The calibration plot (Fig. 3) showed that the predicted
cumulative rates tended to underestimate the observed
cumulative rates at 12 months (P = 0.02 for a statistically
significant difference between predicted and observed).
The results for the calibration coefficient obtained with
the parametric models overlapped with those obtained
Table 1 Validation cohort: baseline characteristics in comparison with the derivation cohort*
Variables Derivation cohort (n = 929)* Validation cohort (n = 904)
Age (years), median (25th, 75th percentiles) 54 (43, 63) 68 (58, 76)
Men, n (%) 562 (60.5) 547 (60.5)
Venous thromboembolism site, n (%)
PE 438 (47.1) 291 (32.2)
Proximal DVT 327 (35.2) 601 (66.5)
Distal DVT 164 (17.7) 12 (1.3)
D-dimer (lg L!1), median (25th, 75th percentiles; range) 355 (236, 558; NA)† 520 (310, 906; 80–6740)
Follow-up time (months), median (25th, 75th percentiles) 43.3 (14.7, 78.5) 21.6 (14.0, 29.1)
Recurrent VTE, n (%) 176 (18.9) 123 (13.6)
DVT, deep vein thrombosis; NA, not available; PE, pulmonary embolism; VTE, venous thromboembolism. *From the derivation paper [7].
†Quantitative D-dimer values available for 832 of 929 patients [7].
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Fig. 2. Observed cumulative rates of recurrence in the validation cohort and by study included in the validation cohort. Few studies provided
substantial data for a follow-up longer than 24 months.
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with the Cox models. The estimated parameters for the
baseline risk function were similar to those obtained from
the derivation cohort (Data S2).
Sensitivity analyses
In the validation cohort, there was a higher risk of
recurrence in younger than in older patients. There were
370 (41%) patients in the validation cohort who were
aged ≤ 65 years. During a median follow-up of
22 months (range: 15.3–30.0 months), 52 (14.0%) of
these patients developed recurrent VTE. In this patient
subset, the calibration slope was comparable to those
obtained in the main analyses with a wider confidence
interval due to the smaller sample size. Details of the
results for patients aged ≤ 65 years are shown in
Data S3.
Discussion
We externally validated the VPM, a clinical prediction
guide developed to estimate the risk of disease recurrence
in patients with a first unprovoked VTE by using sex,
index VTE site and D-dimer levels as predictors. We used
a pooled individual patient database from five studies as
a validation cohort. The ability of the VPM to distinguish
patients’ risk for recurrent VTE in the validation cohort
was at least as good as in the original cohort. The robust-
ness of the VPM in distinguishing between patients at
high or low risk of recurrence in the validation cohort is
evident, despite differences in patient characteristics in the
two cohorts. Hence, patients in the validation cohort were
older, had higher D-dimer levels, less often had distal
DVT, and experienced recurrences over a slightly shorter
time-to-event. Thus, although the derivation cohort
showed a higher cumulative raw frequency of recurrences
than the validation cohort (19% vs. 14%), owing to the
longer average follow-up, a 25% cumulative rate was
reached at 5 years in the derivation cohort [7], whereas it
was reached within 4 years in the validation cohort.
This study, to our knowledge, is the first external vali-
dation of a clinical prediction guide for recurrent VTE
risk. We used rigorous methodology for a time-to-event
model to validate the VPM [9,11,12], and appraised the
model’s performance in the new population to predict
both the relative effect of the risk factors and the absolute
risk of recurrence. In terms of relative increase in risk
across groups, the performance of the VPM in distin-
guishing recurrence risk that was observed in the original
study was confirmed in the validation cohort. In terms of
predicting the absolute recurrence risk, the VPM tended
to slightly underestimate the absolute recurrence rates
found in the validation cohort. Absolute observations
and predictions could only be performed over 12 months
of follow-up, because of limited outcome data after
12 months in the validation cohort studies. The compari-
son might have been affected by the estimation methods,
as the need to account for censoring meant that the
‘observed’ recurrence rates had to be estimated (i.e. with
the Nelson–Aalen estimator), and not simply reported. In
addition, the way in which the observed recurrence rates
were estimated was necessarily different from the way in
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Fig. 3. Calibration plot comparing the observed cumulative rates of
recurrence (as calculated with the Nelson–Aalen estimator) and the
cumulative rates predicted by the Vienna Prediction Model, at
12 months after anticoagulation withdrawal, for five risk groups
(quantiles) into which the validation cohort was divided. Each point
represents the observed–predicted comparison within each group. The
line depicts the results of linear regression used to approximate the
average relationship between the observed and the predicted cumula-
tive rates. Similar results were obtained when the observed and the
predicted rates were plotted for a higher number of groups [20].
Table 2 Predicted risk of recurrence and observed events/rates by risk groups
VPM quintiles*
(number of patients)
Observed VTE recurrences,
no. (raw percentage)
Observed cumulative rate
at 12 months† (95% CI)
Predicted cumulative rate
at 12 months, mean (range)
1 (181) 13 (7.2) 5.1 (2.7–9.9) 3.0 (1.3–3.7)
2 (184) 19 (10.3) 7.1 (4.0–12.5) 4.3 (3.7–4.9)
3 (180) 23 (12.8) 9.0 (5.4–14.9) 5.4 (4.9–6.0)
4 (179) 28 (15.6) 13.3 (8.8–20.3) 6.6 (6.0–7.5)
5 (180) 40 (22.2) 15.9 (10.9–23.4) 9.5 (7.5–18.5)
CI, confidence interval; VPM, Vienna Prediction Model; VTE, venous thromboembolism. *1, 2, 3, 4 and 5 correspond to groups (quintiles) at
increasing predicted risk in the validation cohort. †Calculated with the Nelson–Aalen estimator.
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which the predicted recurrence rates were estimated (i.e.
derived from a Cox model). Notwithstanding the possible
role of the methods used, it is plausible that the different
case mixes in the validation cohort and in the derivation
cohort led to different absolute rates of recurrences.
The clinical implications of this study should be consid-
ered within the context of current clinical practice guide-
lines. On the basis of clinical study data [6,21], one
guideline suggests that patients with unprovoked VTE
who are at high risk of recurrence should be considered
for indefinite anticoagulant therapy if they are at low risk
for bleeding [22]. However, even in patients with a low
bleeding risk, costs (for patients and healthcare systems),
inconvenience, insurability and other potential drawbacks
of indefinite anticoagulation should also be considered.
Thus, distinguishing patients at high or low risk of
recurrent VTE may have far-reaching ramifications. Easy-
to-use prediction models that integrate clinical and labo-
ratory risk factors are therefore attractive for guiding
clinical decisions. In distinguishing recurrent VTE risk,
three prediction rules are currently available: the VPM,
the HERDOO-2, and the DASH score. Of these, the
VPM is now the first to have been externally validated. It
is important for caution to be exercised when such mod-
els are used to predict absolute risks for recurrent VTE in
individual patients, as a model’s performance in discrimi-
nation and calibration is tested in patient groups and not
in individuals [12,23,24].
There are potential limitations of our study. First the
optimal approach to validate a clinical prediction guide by
using survival analyses with the aims of accounting for cen-
soring and being consistent with the derivation methods,
and to use a pooled population as a validation cohort, is
not yet established. Second, as is often the case in clinical
prognostic studies, in our comparisons we did not account
for the uncertainty around predictions, but focused on the
point estimates. Uncertainty around point predictions may
affect the reliability and usability of a prediction model,
especially when we are looking for instruments to use at an
individual level, for which the stochastic uncertainty found
around the average estimates should be even further
inflated. Third, our findings are not applicable to patients
with multiple VTE events, with severe thrombophilia, or
with VTE occurring in the presence of temporary risk fac-
tors (e.g. recent surgery, or estrogen-containing oral con-
traceptives), or in cancer patients. Fourth, quantitative D-
dimer levels were obtained with different D-dimer assays in
the derivation cohort and in the studies comprising the vali-
dation cohort [1]. This might, in part, have contributed to
the different D-dimer level distributions observed in the
two cohorts. The use of different D-dimer levels is inevita-
ble when the VPM is applied in general routine practice.
We therefore believe that, in fact, this can also be seen as a
strength of our analysis, as we could show good discrimina-
tion of the model despite the use of different D-dimer assay
systems.
In conclusion, our study is an important step towards
incorporating a clinical prediction guide for VTE recur-
rence into routine practice. Additional external valida-
tion studies and, most importantly, clinical impact or
management studies [25] are now needed to formally
assess the impact of the VPM on clinically relevant
outcomes when it is used to decide on the duration of
anticoagulation in patients with a first unprovoked
VTE.
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